Mélanome uvéal et tumeurs oculaires CLXS196X2101 A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma Paris SOPHIE PIPERNO-NEUMANN
Mélanome uvéal et tumeurs oculaires IMCgp100-202 A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma Paris
Appareil urinaire MK7902-011 (LEAP-011) A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011). Paris
Appareil urinaire GETUG-StORM-01 A Randomized Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases. Paris SAMAR LINE KRHILI
Mélanome uvéal et tumeurs oculaires PLUME A phase II, monocentric, single arm trial;evaluating the efficacy and safety of;Pembrolizumab in combination with Lenvatinib;in metastatic Uveal MElanoma patients Paris MANUEL RODRIGUES
Appareil urinaire MK3475-992 A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to;Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With;Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder;Cancer (MIBC) (KEYNOTE-992) Paris
Mélanome uvéal et tumeurs oculaires SALOME / IC 2019-13 Follow-up of patients with uveal melanoma adapted to the risk of relapse. Paris SOPHIE PIPERNO-NEUMANN
Appareil urinaire BLAD-RAD01 (GETUG-AFU V07) Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial. Paris